|
|
|
|
|
|||||||
|
Session 87
Poster Session
Hepatitis Virueses: Influence on Morbidity, Mortality, and Response to Antiretroviral Therapy 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 656-M. | Liver Disease Mortality in HIV-HBV Co-Infected Persons C. L. Thio*1, E. C. Seaberg1, R. Skolasky1, J. Phair2, B. Visscher3, A. Munoz1, and D. Thomas 1 1Johns Hopkins Univ., Baltimore, MD; 2Northwestern Univ., Chicago, IL; and 3Univ. of California, Los Angeles
| ||
| 657-M. | Risk of Grade IV Events and Death in HIV Patients Co-Infected with Hepatitis B and/or Hepatitis C Receiving HAART R. Reisler*1, C. Han 2, W. Burman 3, E. Tedaldi 4, and J. Neaton 2 1NIAID, NIH, Bethesda, MD; 2Univ. of Minnesota, Minneapolis; 3Denver Publ. Hlth., CO; and 4Temple Univ., Philadelphia, PA
| ||
| 658-M. | The Effect of Hepatitis C Co-Infection on Survival in the HIV Atlanta VA Cohort Study (HAVACS) in the Post HAART Era D. Rimland*, J. L. Guest, and K. B. Anderson Atlanta VA Med. Ctr., Decatur, GA and Emory Univ, Atlanta, GA
| ||
| 659-M. | HIV/HCV Co-Infection in the HOPS Cohort: Comparison of Mortality, Morbidity, and HAART Utilization E. Tedaldi*1, R. Baker2, A. Moorman3, C. Alzola2, T. Tong3, K. Wood2, L. Walker-Kornegay1, L. Ording-Bauer4, R. Kelly4, J. Esteves4, R. McCabe5, M. Rachel5, and S. Holmberg3 1Temple Univ. Hosp., Philadelphia, PA; 2Cerner Corp, Vienna, VA; 3CDC, Atlanta, GA; 4State Univ. of New York, Stony Brook; and 5Fairmont Hosp., San Leandro, CA
| ||
| 660-M. | Effect of HCV Co-Infection on Hospitalization Rates of HIV-Infected Patients K. Gebo*1, M. Diener-West2, and R. Moore1 1Johns Hopkins Univ. Sch. of Med. and 2Bloomberg Sch. of Publ. Hlth., Baltimore, MD
| ||
| 661-M. | Impact of Viral Hepatitis Co-Infection on Response to Antiretroviral Therapy among a Cohort of Thai HIV-Infected Patients Enrolled in HIV-NAT Trials P. Law*1, C. Duncombe1, G. Dore1, M. Law1, J. Lange2, P. Phanuphak3, and D. A. Cooper1 1Natl. Ctr. in HIV Epidemiology and Clin. Res., Univ. of New South Wales, Australia; 2Natl. AIDS Therapy Evaluation Ctr., Univ. of Amsterdam, The Netherlands; and 3Thai Red Cross AIDS Res. Ctr., Bangkok
| ||
| 662-M. | Viral Hepatitis, Liver Damage, and Antiretroviral Prescribing Patterns in an HIV Community Network C. B. Hare*, M. G. Peters, J. J. Watson, D. G. Mark, and M. A. Jacobson Univ. of California, San Francisco
| ||
| 663-M. | The Safety and Efficacy of Protease Inhibiors (PIs) in Hepatitis C (HCV) Co-Infected Patients D. Dieterich*1, M. Fischl 2, D. Rimland3, and G. Sepulveda4 1Liberty Med., New York, NY; 2Univ. of Miami, FL; 3Atlanta VA Med. Ctr., GA; and 4Programme SIDA, Ponce, PR
| ||
| 664-M. | HIV-HCV Co-Infection in Women: An Urban HIV Clinic Experience N. Tsogas* and R. Orenstein Virginia Commonwealth Univ. and Med. Coll. of Virginia, Richmond
| ||
| 665-M. | Adherence to Guidelines among HIV/HCV Co-Infected Persons and Providers E. H. Teshale*1, S. E. Kellerman2, M. R. Adams2, M. I. Wolfe2, and D. L. Swerdlow2 1CDC and 2DHAP, NCHSTP, Atlanta, GA
|
